- Home
- »
- Medical Devices
- »
-
Presbyopia Correcting Intraocular Lens Market Report, 2033GVR Report cover
Presbyopia Correcting Intraocular Lens Market (2026 - 2033)
Size, Share & Trends Analysis Report By Product (Multifocal, Extended Depth-of-Focus Presbyopia-Correcting IOLs, Accommodative Presbyopia-Correcting IOLs), By Material, By End-use, By Region, And Segment Forecasts
Market Size, 2025
$853.3MMarket Estimate, 2026
$875.7MMarket Forecast, 2033
$1,161.7MCAGR, 2026–2033
4.1%Presbyopia Correcting Intraocular Lens Market Summary
The global presbyopia correcting intraocular lens market size was valued at USD 853.3 million in 2025 and is projected to grow from USD 875.7 million in 2026 to USD 1,161.7 million by 2033, at a CAGR of 4.1% from 2026 to 2033. North America dominated the market, accounting for the largest share of 40.7% in 2025.The growth is driven by the demand for improved vision following cataract surgery and reduced dependence on spectacles.
Source: Grand View Research, IR Documents, Primary Interviews, Paid DatabasesTo learn more about this report,
Download Free Sample Report Key Market Trends & Insights
- By product: Multifocal presbyopia-correcting IOLs segment held the highest market share of 52.9% in 2025.
- By material: Hydrophobic acrylic segment held the highest market share of 71.2% in 2025.
- By end use: Hospitals segment held a leading market share of 39.4% in 2025.
Regional Highlights
- Largest region market: North America (40.7% revenue share, 2025)
- Fastest-growing regional market: Asia Pacific (highest CAGR, 2026-2033)
- By country: The U.S. held the largest market share in 2025.
Market Size & Forecast
- Market size in 2025: USD 853.3 million
- Estimated market size in 2026: 875.7 milllion
- Projected market size by 2033: USD 1,161.7 million
- CAGR (2026-2033): 4.1%
Prism AI by Grand View Research Free to tryAsk a question about the presbyopia correcting intraocular lens marketTry asking✓Every figure cited from GVR research Prefer the report? Download free sample →
These lenses replace the eye's natural lens during surgery and are designed to provide vision at multiple distances or extend the range of functional vision. The growth is further supported by the aging population, the increasing burden of cataracts and presbyopia, and growing patient interest in achieving greater visual independence after surgery. The suitability of these lenses depends on ocular health, patient expectations, clinical assessment, and affordability.
To learn more about this report, Download Free Sample Report A major driver of the market is continued innovation in lens optics aimed at improving visual outcomes and reducing postoperative visual disturbances. Manufacturers are developing lenses that provide a broader range of vision while maintaining contrast sensitivity and minimizing halos and glare. For example, in January 2025, Rayner announced the full commercial release of its RayOne Galaxy and RayOne Galaxy Toric IOLs, featuring a spiral optical design developed to provide a continuous range of vision. The launch followed an initial evaluation involving surgeons from 10 countries and more than 180 treated eyes, according to the company. The development highlights the industry's efforts to introduce differentiated optical technologies and expand options for patients seeking spectacle independence after lens replacement surgery.
To learn more about this report, Download Free Sample Report Another important growth factor is the increasing availability of clinical evidence to help surgeons select suitable presbyopia-correcting lenses for different patient needs. A study published in the Journal of Clinical Medicine in July 2025 compared a next-generation EDOF lens with an enhanced monofocal IOL in 50 patients undergoing bilateral cataract surgery. The study found better intermediate and near visual acuity with the EDOF lens, while distance visual acuity and contrast sensitivity were comparable between the groups. Near-vision spectacle dependence was also lower in the EDOF group. Although the study was limited in size and follow-up, its findings illustrate the potential benefits of advanced lens designs and the importance of evaluating visual outcomes beyond distance acuity alone. Such clinical evidence can support surgeon confidence, patient counselling, and adoption of suitable premium IOLs.
Market Dynamics
The presbyopia-correcting IOLs market is driven by the increasing prevalence of presbyopia, the growing geriatric population, rising cataract surgery volumes, and increasing demand for advanced vision correction solutions. PCIOLs are implanted during cataract surgery to replace the eye’s natural lens and improve vision at multiple distances, addressing presbyopia-related difficulties with near vision. These lenses include multifocal, trifocal, extended depth-of-focus (EDOF), and accommodating IOLs, while toric variants can also correct pre-existing corneal astigmatism. Growing patient preference for reduced spectacle dependence, advancements in optical design and lens materials, and increasing adoption of premium IOLs by ophthalmic surgeons are supporting market growth.
The increasing prevalence of presbyopia and the growing aging population are key drivers of the presbyopia-correcting IOLs market. Presbyopia is an age-related condition in which the eye's natural lens gradually loses its flexibility, making it difficult to focus on nearby objects. As life expectancy increases and more people reach the age at which presbyopia becomes common, the demand for effective near-vision correction is expected to rise. According to the World Health Organization (WHO), more than 800 million people globally have near-vision impairment associated with presbyopia, and the number of presbyopia cases is projected to reach 2.1 billion by 2030. This expanding patient population creates opportunities for PCIOL adoption, particularly among individuals undergoing cataract surgery who want to address presbyopia while replacing their natural lens. Multifocal, trifocal, and extended depth-of-focus (EDOF) IOLs can provide vision at multiple distances and reduce dependence on spectacles, making them relevant options for eligible patients seeking improved visual function after surgery.
Presbyopia-correcting IOLs can cause postoperative visual disturbances, including halos around lights, glare, starbursts, and reduced contrast sensitivity, which may limit their adoption. These effects are particularly associated with multifocal and some diffractive extended depth-of-focus (EDOF) lens designs that distribute light to provide vision at different distances. Although these lenses can reduce dependence on spectacles, visual disturbances may affect activities such as night driving and working in low-light conditions. According to the American Academy of Ophthalmology (AAO), patients receiving presbyopia-correcting IOLs may experience halos and glare, and individuals who drive at night or have demanding visual requirements may find these effects particularly troublesome. These concerns can make patients and ophthalmic surgeons more cautious about choosing PCIOLs over standard monofocal lenses, thereby restraining market growth.
Market Concentration & Characteristics
The presbyopia-correcting IOLs market is competitive, with established ophthalmic device manufacturers competing through differentiated lens designs that improve vision at multiple distances and reduce dependence on spectacles following cataract surgery. Key participants include Alcon, Johnson & Johnson MedTech, Bausch + Lomb, Carl Zeiss Meditec, and Rayner, with portfolios spanning multifocal, trifocal, and extended depth-of-focus (EDOF) IOLs. Competition is increasingly focused on improving visual performance across near, intermediate, and distance ranges, maintaining contrast sensitivity, and reducing postoperative visual disturbances such as halos and glare.
The presbyopia-correcting intraocular lens market is characterized by continuous technological innovation, as manufacturers focus on expanding the range of functional vision after cataract surgery while reducing dependence on spectacles and minimizing unwanted visual disturbances. Innovation is primarily centered on trifocal and multifocal optical designs, extended depth-of-focus (EDOF) technologies, and full-range vision lenses that improve near, intermediate, and distance vision. In April 2025, Alcon introduced Clareon PanOptix Pro in the U.S., incorporating its proprietary ENLIGHTEN NXT optical technology. According to the company, the lens achieves 94% light utilization and half the light scatter of the previous Clareon PanOptix model, with the design intended to improve image contrast across the visual range.
To learn more about this report, Download Free Sample Report Partnerships and collaborations play an important role in the PCIOLs market, as manufacturers combine optical design expertise, adjustable lens technologies, clinical research, and commercial capabilities to improve postoperative visual outcomes and expand access to premium IOLs. These collaborations focus on developing lenses that provide near, intermediate, and distance vision, improving the predictability of refractive outcomes, and addressing patient-specific visual requirements following cataract surgery. A significant recent example is the July 2026 collaboration between Alcon and RxSight, under which the companies announced a non-exclusive agreement to jointly develop adjustable PCIOLs.
Regulatory oversight has a significant impact on the PCIOLs market because these devices are permanently implanted in the eye and are intended to improve visual performance across multiple distances following cataract surgery. Regulatory authorities assess device safety, optical performance, biocompatibility, sterility, manufacturing quality, labeling, and clinical evidence before permitting commercialization. These requirements are particularly important for multifocal, trifocal, and extended depth-of-focus (EDOF) IOLs because their optical designs may affect contrast sensitivity, near and intermediate vision, and the occurrence of visual disturbances such as halos and glare. In the U.S., IOLs are regulated under 21 CFR 886.3600, and applicable Class III devices generally require Premarket Approval (PMA).
The PCIOLs market faces substitution from alternative approaches that address presbyopia and reduce dependence on spectacles, including conventional monofocal IOLs combined with spectacles, monovision correction, multifocal contact lenses, and corneal refractive procedures in clinically eligible patients. For individuals undergoing cataract surgery, a conventional monofocal IOL remains a key alternative because it provides clear vision at a selected focal distance, although patients may still require spectacles for near or intermediate activities. Monovision strategies, in which the eyes are targeted for different focal distances, can also reduce spectacle dependence for selected patients without requiring a multifocal or EDOF IOL. These alternatives can appeal to patients who prioritize affordability or have ocular conditions that make premium presbyopia-correcting lenses less suitable.
Regional expansion is an important growth strategy in the PCIOLs market, as manufacturers seek to increase access to premium multifocal, trifocal, and extended depth-of-focus (EDOF) lenses through regulatory approvals, product launches, distribution networks, and surgeon education. Expansion is particularly relevant in markets where cataract surgery services are well established and patients increasingly seek reduced dependence on spectacles after surgery. However, adoption varies across regions according to healthcare expenditure, out-of-pocket costs, reimbursement policies, surgeon experience, and patient awareness of premium IOL options. For istance, Johnson & Johnson MedTech's international rollout of TECNIS Odyssey in June 2025, which extended the availability of its next-generation presbyopia-correcting IOL across Europe, the Middle East, and Canada.
Analyst Perspective
The presbyopia-correcting IOLs (PCIOLs) market is a specialized segment of the ophthalmic devices market, driven by the rising prevalence of presbyopia, an aging population, and increasing demand for greater visual independence following cataract surgery. Presbyopia-correcting intraocular lenses are artificial lenses implanted inside the eye to replace the natural lens removed during cataract surgery, while providing improved vision across multiple distances and reducing dependence on reading glasses or other corrective eyewear. These lenses include multifocal, trifocal, extended depth-of-focus (EDOF), and accommodating IOLs, with toric variants also available to correct coexisting astigmatism.
Product Insights
The multifocal presbyopia-correcting IOLs segment dominated the market in 2025 and accounted for the 52.9% of the overall revenue. The growth is driven by their ability to provide vision at multiple distances and reduce dependence on spectacles after cataract surgery. These lenses are designed to improve near and distance vision, with some designs also supporting intermediate vision, making them suitable for patients seeking greater visual independence for activities such as reading, using smartphones, and driving. Growing patient awareness of premium IOL options and the availability of advanced optical designs are supporting their use in cataract procedures. For example, manufacturers such as Alcon and Johnson & Johnson MedTech offer multifocal or presbyopia-correcting lens options within their broader intraocular lens portfolios, giving ophthalmic surgeons access to different lens designs based on patients' visual requirements.
The extended depth-of-focus presbyopia-correcting IOLs segment is expected to witness the fastest CAGR of 4.5% over the forecast period. The growth is attributed to the demand for an extended range of functional vision and improvements in lens designs intended to reduce some visual disturbances associated with conventional multifocal optics. EDOF lenses extend the range of focus, particularly for distance and intermediate vision, which can benefit patients who frequently use computers, digital devices, and other objects at arm's length. The segment is also supported by continued product development and the availability of differentiated lens technologiesAdoption is expected to depend on clinical outcomes, patient selection, surgeon familiarity, and the balance between distance, intermediate, and near-vision performance.
Material Insights
The hydrophobic acrylic segment dominated the market in 2025. The growth is supported by its widespread use in foldable intraocular lenses, which can be inserted through relatively small surgical incisions during modern cataract surgery. This material is used in a range of premium presbyopia-correcting IOLs because it can be manufactured into optical designs that support multifocal and extended depth-of-focus functionality. Material selection is also influenced by long-term visual performance and the risk of posterior capsule opacification (PCO), a clouding of the capsule behind the implanted lens that may require additional laser treatment. A clinical evidence review published by the UK's National Institute for Health and Care Excellence (NICE) reported lower rates of Nd:YAG laser capsulotomy with hydrophobic acrylic IOLs than with hydrophilic acrylic IOLs in the included studies, although outcomes can vary by lens design and patient characteristics.
The hydrophilic acrylic segment is expected to witness the fastest CAGR over the forecast period. The growth is driven by its use in foldable IOL designs and its suitability for manufacturing lenses that can be compressed for insertion through small incisions. The material's water-absorbing properties can support flexibility and handling, while its optical and mechanical characteristics allow manufacturers to develop lenses for different surgical requirements. Demand may also benefit from the continued development of premium IOL portfolios and surgeons' need to select lens materials according to patient anatomy, ocular health, and the intended optical outcome.
End Use Insights
The hospitals segment held the largest revenue share in 2025. The growth is supported by their high volume of cataract surgeries, access to ophthalmic surgeons and diagnostic equipment, and ability to manage patients requiring comprehensive preoperative assessment and postoperative care. Hospitals are important purchasing centers for presbyopia-correcting IOLs because lens selection involves assessing visual needs, measuring ocular parameters, discussing the potential benefits and limitations of premium lenses, and ensuring appropriate surgical follow-up. Their established procurement systems and relationships with intraocular lens (IOL) manufacturers also support the availability of different multifocal and EDOF lens options. The American Academy of Ophthalmology confirms that cataract surgery can be performed in hospitals or outpatient surgical centers and that the surgeon measures the eye to determine the appropriate IOL power before surgery.
To learn more about this report, Download Free Sample Report The ophthalmic clinics segment is anticipated to grow at fastest CAGR over the forecast period. The growth is attributed to the expansion of specialized eye-care services, increasing availability of outpatient cataract surgery, and greater access to consultations focused on refractive outcomes and reduced spectacle dependence. Dedicated ophthalmic clinics and eye hospitals can provide patient assessment, cataract diagnosis, biometry, IOL counselling, surgical procedures where facilities are available, and postoperative monitoring. Their specialized focus allows surgeons to discuss the differences between multifocal and EDOF lenses and match lens selection to patients' visual requirements, lifestyle, and tolerance for potential visual disturbances.
Regional Insights
The North America presbyopia correcting intraocular lens market accounted for the largest revenue share of 40.7% in 2025. The growth is supported by established ophthalmic care infrastructure, high availability of advanced cataract surgery technologies, and demand for premium vision correction. The U.S. and Canada have well-developed networks of ophthalmology clinics, hospitals, and ambulatory surgery centers, enabling patients to access multifocal, trifocal, and extended depth of focus (EDOF) lenses. The availability of experienced cataract surgeons and growing interest in reducing dependence on spectacles also support adoption. The introduction of new lens technologies also supports product choice; for example, Alcon announced the European launch of its Clareon Vivity EDOF lens in March 2025, reflecting continued innovation in presbyopia-correcting IOLs. Similar advances in premium IOL technology help sustain interest in advanced cataract surgery across North America
The U.S. presbyopia correcting IOLs market is experiencing robust growth, driven by large population undergoing cataract surgery, established ophthalmic surgical facilities, and patient interest in improving near, intermediate, and distance vision with reduced dependence on glasses. Demand is supported by the availability of multifocal, trifocal, EDOF, and light-adjustable lens technologies, as well as continued product development by major ophthalmic device manufacturers. Medicare generally covers cataract surgery with a conventional IOL but does not cover the additional functionality of a presbyopia-correcting IOL, meaning patients may have to pay extra for premium lens options. This creates a market in which adoption depends not only on clinical suitability but also on household income, patient expectations, and willingness to pay.
Europe Presbyopia Correcting Intraocular Lens Market Trends
The Europe PCIOLs market accounted for the significant revenue share in 2025. The growth is supported by an aging population, established ophthalmic care services, and the availability of advanced cataract surgery technologies. Demand is influenced by the large number of cataract procedures performed across European countries and growing interest in improving visual quality after surgery. However, adoption varies by country depending on public healthcare funding, private insurance coverage, patient affordability, and access to premium ophthalmic services. Product innovation is also supporting the market. In March 2025, Alcon announced CE Mark approval and plans for the European commercialization of its Clareon Vivity and Clareon Vivity Toric EDOF lenses, expanding the range of presbyopia-correcting options available to surgeons.
The UK PCIOLs market is steadily growing.The growth is supported by an aging population, established cataract surgery services, and demand for improved vision following lens replacement. Adoption is influenced by the distinction between NHS-funded treatment and privately funded premium lens procedures, as conventional monofocal IOLs remain the standard option in many publicly funded pathways. In May 2024, Community Health and Eyecare (CHEC) announced that it would offer extended monofocal lenses to eligible NHS patients, demonstrating efforts to broaden access to lenses that provide a wider range of vision.
The Spain presbyopia correcting IOLs market is experiencing significant growth in global presbyopia correcting IOLs (PCIOLs)market. The growth is attributed to the aging population, established cataract surgery services, and demand for improved vision among patients undergoing lens replacement. According to Eurostat data for 2023, Spain performed approximately 890 cataract surgeries per 100,000 inhabitants, indicating an established base of cataract procedures through which premium IOLs may gain adoption. A relevant industry development occurred in March 2025, when Alcon announced European commercialization of Clareon Vivity; its announcement included commentary from a Spanish ophthalmology specialist on the lens's potential role in addressing patients' visual needs. Wider access to advanced lens designs may support market development, although public funding arrangements and additional patient costs remain important factors in adoption.
Asia Pacific Presbyopia Correcting Intraocular Lens Market Trends
Asia-Pacific PCIOLs market is expected to witness fastest CAGR of 5.2% over the forecast period. The growth is driven by a growing older population, increasing cataract surgery demand, improving ophthalmic care infrastructure, and expanding access to advanced medical technologies. Countries such as China, Japan, South Korea, India, and Australia offer different growth opportunities based on healthcare spending, surgical capacity, private healthcare development, and patient affordability. The expansion of specialist eye hospitals and private ophthalmology clinics is helping increase access to premium lens technologies, although the adoption rate varies considerably between urban and rural areas.
China's presbyopia correcting IOLs market is experiencing rapid expansion, driven by demand for cataract treatment, improving access to ophthalmic services, and increasing interest in advanced vision correction. Major cities have established ophthalmology hospitals and specialist clinics that provide access to premium cataract surgery technologies, while growing awareness of multifocal, trifocal, and EDOF lenses is supporting patient interest. A relevant clinical development occurred in June 2025, when the Chinese Journal of Ophthalmology published an expert consensus on the clinical application of presbyopia-correcting IOLs. The consensus addressed the definition and appropriate clinical use of these lenses, reflecting efforts to improve patient selection and support evidence-based use.
South Korea's presbyopia correcting IOLs market is experiencing strong growth, driven by an established healthcare system, access to advanced ophthalmic procedures, and demand for improved visual outcomes after cataract surgery. Private health insurance and out-of-pocket spending can influence the uptake of premium lenses, particularly among patients seeking reduced dependence on spectacles. A nationwide study published in 2024 examined cataract surgery utilization and intraocular lens use in South Korea between 2016 and 2020. It reported a 36.8% increase in cataract operations over that period and found that non-National Health Insurance-covered IOLs were used more frequently among patients younger than 65 than among older patients in the studied cases. Although these findings cover IOLs beyond PCIOLs alone, they demonstrate the role of private insurance and patient payment in the broader premium lens market.
Latin America Presbyopia Correcting Intraocular Lens Market Trends
The Latin America presbyopia correcting IOLs (PCIOLs) Marketis emerging as a high-growth market, supported by the need to address cataract-related vision impairment, and gradual improvements in ophthalmic care access. A 2024 study published in the Pan American Journal of Public Health examined vision impairment among adults aged 60 years and older across Latin America and the Caribbean, identifying cataract as the leading cause of blindness in the population studied and reporting substantial differences in effective cataract surgical coverage between countries. These findings highlight the need to expand cataract care and improve access to treatment.
The Brazil presbyopia correcting IOLs market is growing. The public Unified Health System (SUS) provides cataract surgery services, while private hospitals and eye clinics offer additional opportunities for patients seeking premium IOL options. However, demand for presbyopia-correcting lenses depends on household purchasing power, private insurance coverage, access to specialist surgeons, and the additional cost of advanced implants. Public-sector initiatives to expand cataract surgery can increase access to lens replacement procedures, although they do not necessarily translate into equivalent growth in premium PCIOL use. For example, Brazil's Ministry of Health has maintained programs aimed at expanding access to specialized care, including ophthalmology services and cataract surgery through public healthcare initiatives.
Middle East & Africa Presbyopia Correcting Intraocular Lens Market Trends
The Middle East & Africa PCIOLs market is witnessing steady growth, supported by increasing demand for cataract treatment, expanding private healthcare infrastructure, and investment in specialized ophthalmic services, particularly in Gulf countries. The region presents different adoption patterns: higher-income markets have greater capacity to offer premium lenses, while affordability and access to specialist care remain more significant barriers in several African countries. Demand for multifocal, trifocal, and EDOF IOLs is influenced by surgeon availability, patient awareness, reimbursement arrangements, and the cost of imported devices. Investment in advanced eye care facilities and the availability of modern surgical equipment are improving access to cataract procedures in selected markets.
The Saudi Arabia PCIOLs market is experiencing notable growth, driven by healthcare modernization, investment in specialized eye care, and demand for advanced surgical treatments among an aging population. Vision 2030 initiatives are encouraging improvements in healthcare access, service quality, and specialist capacity, while private hospitals and ophthalmology centers provide opportunities for premium cataract surgery and advanced lens implantation. A relevant development occurred in November 2024, when a royal order approved the founding law for the transformation of King Khaled Eye Specialist Hospital into King Khaled Eye Specialist Hospital and Research Center as an independent nonprofit organization under the Royal Commission for Riyadh City. The institution's specialized role in eye care supports the country's broader ophthalmology infrastructure.
Key Presbyopia Correcting Intraocular Lens Company Insights
The market is competitive, with medical device manufacturers focusing on advancements in optical design, lens materials, and technologies that improve vision across near, intermediate, and distance ranges. Market participants are increasingly emphasizing premium IOL technologies, including multifocal, trifocal, extended depth-of-focus (EDOF), and accommodating lenses, alongside advanced toric designs that address coexisting astigmatism.
Key Presbyopia Correcting Intraocular Lens Companies:
The following key companies have been profiled for this study on the presbyopia correcting intraocular lens market
-
Bausch & Lomb Incorporated
-
Alcon Inc.
-
Johnson & Johnson Vision
-
Carl Zeiss Meditec AG
-
Rayner Intraocular Lenses Limited
-
HOYA Corporation
-
Beaver-Visitec International, Inc.
-
SIFI S.p.A.
Competitive Benchmarking
Category
Operating Strategies
Competitive Edge
Weakness
Established Players (Bausch & Lomb Incorporated; Alcon Inc.; Johnson & Johnson Vision; Carl Zeiss Meditec AG)
- Expand portfolios of multifocal, trifocal, and extended depth-of-focus (EDOF) IOLs to address near, intermediate, and distance vision requirements.
- Invest in advanced optical designs, clinical evidence, surgeon education, and premium lens delivery systems to improve visual outcomes and strengthen market penetration.
- Strong brand recognition, established surgeon relationships, broad distribution networks, and extensive ophthalmic product portfolios support market presence.
- Advanced optical technologies and established clinical evidence support product differentiation across premium lens categories.
- High R&D, clinical validation, and regulatory compliance costs increase product development complexity.
- Premium pricing and variable reimbursement coverage can limit adoption, while the risk of glare, halos, and reduced contrast sensitivity may affect patient suitability and satisfaction.
Emerging Players (Rayner Intraocular Lenses Limited; HOYA Corporation, Beaver-Visitec International, Inc.)
- Focus on differentiated technologies, including accommodating IOLs, innovative optical designs, and alternative approaches to delivering a broader range of vision.
- Prioritize clinical development, strategic partnerships, regulatory approvals, and commercialization of specialized lens technologies.
- Focused R&D enables companies to explore differentiated technologies and address unmet needs in presbyopia correction.
- Specialized portfolios and flexible development strategies support innovation in visual performance and patient-specific treatment approaches.
- Limited commercial reach, financial resources, and brand recognition can constrain adoption relative to established manufacturers.
- Dependence on clinical validation, regulatory clearance, surgeon acceptance, and reimbursement can delay commercialization and market expansion.
Recent Development
-
In June 2025, Johnson & Johnson Vision announced the launch of its TECNIS Odyssey intraocular lens (IOL) in Europe, the Middle East, and Canada, expanding its portfolio of presbyopia-correcting IOLs. The lens features a full-range-of-vision optical design intended to provide continuous vision at near, intermediate, and distance ranges, helping patients with presbyopia reduce their dependence on spectacles following cataract surgery.
-
In April 2025, Alcon announced the introduction of Clareon PanOptix Pro, a next-generation trifocal presbyopia-correcting intraocular lens (PCIOL) for cataract patients in the U.S. The lens incorporates ENLIGHTEN NXT optical technology, achieving 94% light utilization and 50% less light scatter than the previous Clareon PanOptix lens. Its optical design provides vision across near, intermediate, and distance ranges and demonstrated a 16% increase in optical image contrast between distance and intermediate vision in bench testing.
Presbyopia Correcting Intraocular Lens Market Report Scope
Report Attribute
Details
Market size value in 2025
USD 853.3 million
Market size value in 2026
USD 875.7 million
Revenue forecast in 2033
USD 1,161.7 million
Growth rate
CAGR of 4.1% from 2026 to 2033
Base year for estimation
2025
Historical data
2021 - 2024
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million and CAGR from 2026 to 2033
Report coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered
Product, material, end use, region
Regional scope
North America; Europe; Asia Pacific; Latin America; MEA
Country scope
U.S.; Canada; Mexico; U.K.; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; Thailand; South Korea; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait
Key companies profiled
Bausch & Lomb Incorporated; Alcon Inc.; Johnson & Johnson Vision; Carl Zeiss Meditec AG; Rayner Intraocular Lenses Limited; HOYA Corporation; Beaver-Visitec International, Inc.; SIFI S.p.A.
Customization scope
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional, and segment scope
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
Presbyopia Correcting Intraocular Lens Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global presbyopia correcting Intraocular Lens market report based on product, material, end use, and region:
To learn more about this report, Download Free Sample Report -
Product Outlook (Revenue, USD Million, 2021 - 2033)
-
Multifocal Presbyopia-Correcting IOLs
-
Extended Depth-of-Focus Presbyopia-Correcting IOLs
-
Accommodative Presbyopia-Correcting IOLs
-
Other Presbyopia-Correcting IOLs
-
-
Material Outlook (Revenue, USD Million, 2021 - 2033)
-
Hydrophobic Acrylic
-
Hydrophilic Acrylic
-
Silicone
-
Others
-
-
End Use Outlook (Revenue, USD Million, 2021 - 2033)
-
Hospitals
-
Ambulatory Surgery Centers (ASCs)
-
Ophthalmic Clinics
-
Eye Research Institutes
-
Others
-
-
Regional Outlook (Revenue, USD Million, 2021 - 2033)
-
North America
-
U.S.
-
Canada
-
Mexico
-
-
Europe
-
UK
-
Germany
-
France
-
Italy
-
Spain
-
Norway
-
Denmark
-
Sweden
-
-
Asia Pacific
-
China
-
Japan
-
South Korea
-
Thailand
-
Australia
-
India
-
-
Latin America
-
Brazil
-
Argentina
-
-
MEA
-
South Africa
-
Saudi Arabia
-
UAE
-
Kuwait
-
-
Research Methodology
The presbyopia correcting intraocular lens market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each presbyopia correcting intraocular lens market segment quantified using the revenue-capture definitions in the table below.
Segment Definition
Segment - Product
Revenue capture definition
Multifocal Presbyopia-Correcting IOLs
Revenue is generated through the commercialization of premium intraocular lenses designed with distinct refractive or diffractive zones that split light to deliver simultaneous near, intermediate, and distance focal points. Ophthalmic manufacturers earn premium revenue margins per unit from direct surgical center orders, driven by patients undergoing elective cataract or clear lens exchange procedures who seek complete independence from reading glasses.
Extended Depth-of-Focus Presbyopia-Correcting IOLs
Revenue flows from the distribution of advanced optical implants that utilize wave-front shaping or non-diffractive optical profiles to stretch a single continuous focal zone from distance into intermediate ranges. Companies capture value by marketing these lenses to safety-focused surgeons and patients as solutions that minimize visual side effects such as glare, halos, and loss of contrast sensitivity while maintaining high clinical out-of-pocket pricing tiers.
Accommodative Presbyopia-Correcting IOLs
Revenue is captured through the sale of dynamic, flexible lens platforms engineered to shift position or alter curvature within the eye's capsular bag in response to ciliary muscle contractions. Manufacturers derive capital and product revenue by offering a mechanical, non-diffractive alternative that mimics the eye’s natural focusing action without splitting incoming light rays, supported by high per-unit acquisition costs and specialized surgical implantation kits.
Other Presbyopia-Correcting IOLs
Revenue encompasses niche and emerging presbyopia-correcting lens architectures, including hybrid multifocal-EDOF designs, custom-built light-adjustable lenses (LALs) requiring post-operative UV light treatment units, and specialized toric presbyopia-correcting variants that simultaneously treat presbyopia and corneal astigmatism.
Segment - Material
Revenue capture definition
Hydrophobic Acrylic
Revenue is generated through the high-volume distribution of hydrophobic acrylic polymer lenses engineered to resist water absorption and minimize posterior capsule opacification (PCO). This dominant material segment produces steady, high-margin revenue through foldable pre-loaded injection delivery systems that enable seamless micro-incision cataract surgery (MICS).
Hydrophilic Acrylic
Revenue flows from the commercialization of high-water-content acrylic lenses known for exceptional uveal biocompatibility and flexible structural handling. Manufacturers monetize this segment through cost-effective production models, capturing value across clinical accounts that prioritize minimal intraocular inflammation, soft mechanical unfold dynamics, and tissue-friendly polymer profiles.
Silicone
Revenue is captured through the supply of high-refractive-index, flexible silicone-based intraocular implants. Income is derived from established product lines offering rapid intraocular unfolding and optical clarity, sustained by steady wholesale replacement contracts across specialized surgical centers.
Others
Revenue includes alternative or next-generation biomaterials, such as polymethyl methacrylate (PMMA) rigid lenses, hydrophobic-hydrophilic copolymer hybrids, and proprietary nanocomposite materials designed to optimize light transmission, blue-light filtering, and long-term ocular stability.
Segment - End Use
Revenue capture definition
Hospitals
Revenue is generated through large-scale capital budget allocations, public healthcare tenders, and multi-site group purchasing organization (GPO) procurement contracts. Manufacturers earn bulk revenue via high-volume lens shipments, bundled surgical packs, custom phacoemulsification cassette integration, and multi-year facility supply agreements.
Ambulatory Surgery Centers (ASCs)
Revenue flows from high-throughput commercial supply networks tailored to lean, outpatient surgical facilities. Income is driven by pre-loaded, ready-to-inject premium IOL delivery cassettes and rapid-turnaround delivery logistics that minimize surgical setup times and lower per-case operational costs.
Ophthalmic Clinics
Revenue is captured through direct-to-practice physician accounts, specialized eye care buying groups, and out-of-pocket patient billing frameworks. Medtech providers generate premium margins by supporting clinics that offer elective refractive lens exchange (RLE) and premium cataract upgrade packages directly to self-paying patients.
Eye Research Institutes
Revenue is derived from distributing academic-grade, specialized IOL configurations, custom optical prototypes, and experimental lens models to university laboratories and clinical trial sites. This segment commands specialized pricing structures supported by clinical research grants and corporate-sponsored R&D partnerships.
Others
Revenue encompasses secondary surgical and training facilities, including academic teaching hospitals, military medical centers, and international ophthalmic mission projects purchasing bulk standardized intraocular inventory.
Estimation Model
Title
Key Question
Process Steps
Data Sources
Scope Definition
What types of presbyopia-correcting IOLs are included in the market?
1. Define presbyopia-correcting IOL product categories.
2. Segment by lens type, material, and end user.
3. Establish product inclusion and exclusion criteria.
4. Establish the base year and forecast period (2026-2033).
FDA, manufacturer product portfolios, regulatory databases, ophthalmology associations.
Build the Product Base
How many procedures represent potential demand for presbyopia-correcting IOLs?
1. Estimate annual cataract surgery and refractive lens exchange volumes.
2. Identify eligible patients and addressable procedures.
3. Assess premium IOL utilization across healthcare settings.
4. Forecast procedure volumes using demographic and surgical trends.
National health databases, ophthalmology associations, hospital statistics, clinical surveys.
Estimate Penetration
What proportion of eligible procedures use presbyopia-correcting IOLs?
1. Estimate IOL penetration in eligible lens replacement procedures.
2. Assess adoption by lens type, including multifocal, trifocal, EDOF, and accommodating IOLs.
3. Evaluate adoption by country, surgeon, and healthcare setting.
4. Forecast penetration based on technology adoption, patient preferences, and affordability.
ESCRS and ASCRS surveys, clinical publications, surgeon interviews, manufacturer disclosures.
Revenue Conversion
How does PC-IOL implantation volume translate into market revenue?
1. Collect ASPs by lens type and geography.
2. Calculate revenue from annual PC-IOL unit sales.
3. Segment revenue by product type, application, and end user.
4. Validate estimates against company revenues and sales data.
Manufacturer annual reports, product pricing, distributor data, hospital procurement records.
Delivered Customizations
This report has been delivered with the following In-depth customizations
Client Request
Customization Delivered
Value Adds
Material Segment Analysis
Conducted a detailed analysis of materials used in presbyopia-correcting intraocular lenses (PCIOLs), covering hydrophobic acrylic, hydrophilic acrylic, silicone, and other relevant materials used in lens manufacturing. The assessment examined material properties, optical clarity, biocompatibility, flexibility, durability, and their suitability for multifocal, trifocal, and extended depth of focus (EDOF) IOL designs. The study also evaluated how material characteristics influence lens implantation, postoperative performance, visual quality, and the risk of complications such as posterior capsule opacification. In addition, the analysis considered manufacturer preferences, technological developments in lens materials, product portfolio differentiation, manufacturing costs, and the impact of material selection on product pricing and market adoption.
Enables stakeholders to understand how material selection influences PCIOL performance, product differentiation, and commercial opportunities. The analysis supports manufacturers in identifying material preferences, evaluating product development priorities, and assessing opportunities to improve visual outcomes and long-term lens performance.
Porter Analysis
Conducted a comprehensive Porter's Five Forces analysis of the global presbyopia-correcting IOLs market, evaluating competitive rivalry among established ophthalmic device manufacturers, the threat of new entrants, supplier bargaining power, buyer bargaining power, and the threat of substitutes. The assessment considered competition among multifocal, trifocal, EDOF, and other presbyopia-correcting lens technologies, along with the importance of clinical evidence, surgeon familiarity, regulatory approvals, manufacturing capabilities, and established distribution networks. It also examined the influence of ophthalmic surgeons, hospitals, ambulatory surgery centers (ASCs), and purchasing groups on product selection and procurement. Economic factors, including premium IOL pricing, reimbursement limitations, out-of-pocket patient expenditure, healthcare spending, and manufacturing costs, were evaluated to understand their influence on competitive intensity and market profitability.
Enables stakeholders to assess the competitive structure and commercial attractiveness of the PCIOLs market. The analysis supports decisions related to market entry, product differentiation, pricing, partnerships, and portfolio expansion. It also helps manufacturers understand how supplier costs, surgeon preferences, procurement practices, and patients' willingness to pay for premium vision correction influence market penetration and profitability.
Geographic Analysis
Conducted a detailed geographic assessment of the PCIOLs market across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, with country-level evaluation of major markets. The study examined regional differences in cataract surgery volumes, aging populations, presbyopia prevalence, healthcare infrastructure, ophthalmic surgeon availability, premium IOL adoption, reimbursement and policies, and regulatory requirements. The analysis also assessed differences in patient affordability, private healthcare expenditure, insurance coverage, and demand for reduced dependence on spectacles following cataract surgery. Macroeconomic factors, including GDP growth, inflation, currency fluctuations, import duties, manufacturing costs, and healthcare investment, were considered alongside product availability, distribution networks, and the presence of established ophthalmic device manufacturers.
Enables stakeholders to identify attractive regional markets and prioritize expansion and investment opportunities. The analysis supports the development of region-specific pricing, distribution, and commercialization strategies based on patient affordability, healthcare infrastructure, and premium IOL adoption.
About the Author(s)
Medical Devices Research Team
Healthcare · Medical DevicesThis report was authored by the medical devices research team at Grand View Research - comprising two research analysts, one senior research analyst, and one industry expert - with specialized expertise in the medical devices segment of the healthcare industry. All findings are based on proprietary healthcare databases, executive interviews, and regulatory analysis, subject to internal peer review prior to publication.
Last Updated:
Speak to Analyst
Customize this report to your needs - add regions, segments, or data points, with 20% free customization.
Or view our licence options:
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
